COMPOUND PROFILE / PEPTIDES & ANALOGUES
PT-141 / Bremelanotide.
Research draftBremelanotide, also called PT-141, is a melanocortin receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Bremelanotide, also called PT-141, is a melanocortin receptor agonist.
Mechanism
It acts through central melanocortin signalling relevant to sexual desire.
Human research
Controlled clinical development supports a specific sexual-desire indication; early male studies are a separate evidence context.
Preclinical & other research
Receptor experiments established its melanocortin activity.
Safety & unknowns
Nausea, transient blood-pressure increases and pigmentation changes are important. Contraindications depend on the approved label.
Regulatory status
Vyleesi is a US prescription product for a defined group of premenopausal women; it is not broadly approved for every sexual complaint.
Reported use & evidence
The supplied PT-141 / Bremelanotide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.